Welcome to the tag category page for Controlled substance!
Pregabalin is a medication that is used to treat nerve pain caused by conditions such as diabetes or shingles. It is also used to treat seizures and anxiety. Pregabalin works by slowing down impulses in the brain that cause pain. It comes in the form of capsules or an oral solution. The most common side effects are dizziness, drowsiness, and nausea. Research has shown that pregabalin is effective in reducing pain caused by nerve damage and improving sleep quality.
PlushCare is an online medical care provider offering primary care, urgent care, mental health, and therapy services. They have an app and website where patients can receive medical treatment and prescriptions from licensed providers in all 50 states, and are covered by major insurances. PlushCare was founded in 2014 and is a legitimate platform with high approval ratings. They offer a membership fee that covers access to their technology platform, online appointment booking, messaging, and care coordination services. Patients cannot get controlled substances like Xanax from PlushCare, but can receive most other psychiatric medications.
Brivaracetam (brand name Briviact) is an anticonvulsant chemically related to levetiracetam and acts as a ligand at the synaptic vesicle protein 2A (SV2A) with substantially higher affinity than levetiracetam. It is approved as adjunctive therapy for partial‑onset seizures across a wide pediatric and adult age range and is available as a branded product and in generic formulations. Clinically it is positioned as an alternative to levetiracetam (Keppra) for patients who may benefit from greater receptor selectivity, though effectiveness and tolerability vary individually. Brivaracetam is classified as a Schedule V controlled substance in some jurisdictions because higher doses have been associated with euphoria. Common and notable adverse effects include irritability, anxiety and, in some cases, psychotic symptoms such as hallucinations or delusions, which require monitoring. The market includes the originator pharmaceutical company UCB as the promoter of Briviact, while generic manufacturers supply lower‑cost alternatives, shaping prescribing and reimbursement dynamics in epilepsy treatment.
